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Abstract
Serum des-gamma-carboxy prothrombin (DCP) is commonly used to detect hepatocellular
carcinoma (HCC). This review focuses on the clinical features of DCP-positive HCC and the
molecular function of DCP in HCC. DCP-positive HCC demonstrates more aggressive clinico-
pathological features than DCP-negative HCC. Analysis of the biological effects of DCP revealed
that DCP acts as a growth factor in both an autocrine and paracrine manner. DCP stimulates HCC
cell proliferation through the Met-Janus kinase 1-signal transducer and activator of transcription
3 signaling pathway, whereas for vascular endothelial cells, it stimulates cell proliferation and
migration through the kinase insert domain receptor-phospholipase C-gamma-mitogen-activated
protein kinase signaling pathway.
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Serum des-γ-carboxy prothrombin (DCP) is commonly used to detect hepatocellular carcinoma (HCC).  
This review focuses on the clinical features of DCP-positive HCC and the molecular function of DCP 
in HCC.  DCP-positive HCC demonstrates more aggressive clinicopathological features than DCP-
negative HCC.  Analysis of the biological eﬀects of DCP revealed that DCP acts as a growth factor in 
both an autocrine and paracrine manner.  DCP stimulates HCC cell proliferation through the Met-
Janus kinase 1-signal transducer and activator of transcription 3 signaling pathway,  whereas for 
vascular endothelial cells,  it stimulates cell proliferation and migration through the kinase insert 
domain receptor-phospholipase C-γ-mitogen-activated protein kinase signaling pathway.
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epatocellular carcinoma (HCC) is one of the 
most common abdominal cancers in the world 
[1,  2].  The number of deaths per year due to HCC is 
estimated to be over 30,000 in Japan [3] and over one 
half million worldwide [4].  Recently,  early-stage 
HCC has been treated by surgical resection or radio-
frequency ablation,  and the prognosis for patients 
receiving these therapies has improved [5].  However,  
there is no eﬀective therapy for patients with 
advanced HCC [5]; therefore,  early detection of 
HCC is important.
　 Tumor markers are widely used for early detection 
of HCC.  Alpha-fetoprotein (AFP),  a primary tumor 
marker for HCC,  has been used to detect and monitor 
HCC [6-9].  In general,  the sensitivity of AFP is 
acceptable,  though it is not always acceptable for 
patients with early HCC,  since the AFP levels are 
sometimes low in these patients [10,  11].  Des-γ
-carboxy prothrombin (DCP) is also commonly used to 
detect HCC.  DCP is an abnormal prothrombin with-
out carboxylation of 10 glutamic acid residues at its 
N-terminus and is devoid of coagulation activity [12].  
Due to the lack of carboxylation of the carbon atom at 
the γ-position,  it is called des-γ-carboxy prothrombin.  
In 1984,  Liebman et al.  [13] ﬁrst reported that 
serum DCP levels are increased in patients with HCC 
based on a competitive radioimmunoassay.
　 Because AFP and DCP behave independently in 
serum,  they can complement each other for the diag-
nosis of HCC [9,  14-16].  Hence,  the combined use 
of AFP and DCP increases sensitivity as well as 
speciﬁcity and has been commonly used in the diagno-
sis of HCC [17,  18].  Although AFP is superior to 
DCP as a diagnostic tool for early detection of HCC,  
DCP is more reliable than AFP as a prognostic tool 
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for HCC in terms of reﬂecting the invasive character-
istics [19,  20].
　 This review focuses on the association between 
DCP and the clinical development of HCC.  We also 
describe our series of reports concerning the eﬀect of 
DCP on the development of HCC.
Serum DCP is a Prognostic Factor for HCC
　 DCP has been reported to be a clinical prognostic 
factor for recurrence and survival after hepatectomy 
[15,  21-24],  liver transplantation [25,  26],  radio-
frequency ablation treatment [27-29],  and transarte-
rial chemoembolization treatment [30].  These ﬁndings 
are based on the fact that the serum DCP level cor-
relates with tumor diameter,  which reﬂects HCC cell 
growth [31,  32].
Serum DCP Level and Portal Vein Invasion  
by HCC
　 The serum DCP level correlates with the number 
of tumors,  the histological tumor grade of HCC dif-
ferentiation,  the development of portal vein invasion,  
and tumor size [23,  32-34].  The serum DCP level is 
the most signiﬁcant predictor for the development of 
portal vein invasion [35-37].  Consistent with these 
reports,  there is a positive correlation between serum 
DCP level and vascular invasion in adult HCC patients 
who undergo living donor liver transplantation [25].  
In this report,  it was demonstrated that the incidence 
of positive histological vascular invasion in patients 
with a DCP level above 300mAU (arbitrary units)/
mL was signiﬁcantly higher than that in those with a 
DCP level below 300mAU/mL,  demonstrating that 
high serum DCP correlates with histological vascular 
invasion and could be a strong prognostic indicator.
Characteristics of DCP-predominant HCC
　 A milder form of hepatitis is the source of HCC in 
patients with HCV-related HCC,  and DCP-
predominant HCC is associated with a more stable 
platelet count than AFP-predominant HCC [38].  
Among patients with HBV-related HCC,  those with a 
high serum DCP level have more aggressive tumor 
characteristics and a shorter median survival time 
than those with a low serum DCP level [39].  Even 
after excluding patients with Child-Pugh class C and 
advanced tumor stages at diagnosis,  a high DCP level 
is still an independent predictor of survival,  suggest-
ing that the hepatocarcinogenic mechanisms in DCP-
predominant HCC may diﬀer from those in AFP-
predominant HCC.
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Fig. 1　 The vitamin K-dependent carboxylation reaction.  The glutamic acid residues (Glu) of the prothrombin precursor and des-γ-car-
boxy prothrombin (DCP) are carboxylated into gamma-carboxy glutamic acid (Gla) residues by GGCX,  which requires reduced vitamin K as 
a cofactor.  Normal prothrombin has 10Gla residues,  and all are required for the coagulation activity.
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Molecular Basis for DCP Production in HCC
　Vitamin K-dependent γ-glutamyl carboxylase 
(GGCX) plays a crucial role in converting DCP into 
normal prothrombin via vitamin K epoxide reductase 
(VKOR) [12,  40,  41].  GGCX mediates the post-
translational modiﬁcation required for the activity of 
all vitamin K-dependent proteins including prothrom-
bin [42-44] (Fig.  1).  It has been reported that DCP-
producing HCC shows low GGCX activity [45],  and 
a point mutation of the GGCX gene causes insuﬃcient 
GGCX enzyme activity in patients with blood coagula-
tion disorders [46-49].
　 However,  there are no reports referring to allelic 
variants of GGCX in HCC.  We performed a cDNA 
sequence analysis of GGCX using 2 groups of HCC 
cell lines classiﬁed as DCP-positive (Hep3B,  HepG2,  
HuH1,  HuH7 and PLC) and DCP-negative 
(SK-Hep-1,  HLE,  HLF and JHH1),  but neither a 
point mutation nor a missense mutation was found 
[50],  and a sequence analysis with a sense primer did 
not detect a sequence in DCP-positive HCC cell lines.  
In contrast,  a sequence analysis with an antisense 
primer in DCP-positive HCC cell lines revealed that 
2 waveforms of the sequence overlapped from posi-
tions 162 to 213.  These overlapped sequences were 
identiﬁed as the exon 1 and exon 2 sequences 
of GGCX by a BLAST (NCBI) homology 
search analysis.  The minor sequence was 
identiﬁed as a GGCX alternative splicing vari-
ant lacking exon 2 (Δ2GGCX) (Fig.  2).  When 
the HCC cell lines were analyzed,  only Δ
2GGCX was expressed in the DCP-positive 
HCC cell lines.
　 We further examined the function of Δ
2GGCX and demonstrated that transfection of 
a low proportion of Δ2GGCX cDNA causes 
DCP production in DCP-negative HCC cell 
lines [50],  suggesting that Δ2GGCX could 
function as a dominant-negative inhibitor of wild 
type GGCX.  It may be that the GGCX struc-
ture is altered in Δ2GGCX,  which aﬀects the 
regions responsible for the active site or the 
binding site of coenzymes,  including VKOR 
and calumenin [51-54].
　 Another possible mechanism for DCP pro-
duction has been reported in some studies.  The 
uptake of vitamin K,  a GGCX coenzyme,  is 
suppressed in 2 rat hepatoma cell lines,  MH7777 and 
H4IIE [51].  DCP production due to a deﬁciency of 
vitamin K has also been reported in HCC [45,  55,  
56].
DCP Stimulates Cell Proliferation  
in HCC Cell Lines
　 Many studies have reported that serum and tissue 
DCP expression reﬂect the biological malignant 
potential of HCC [21,  22,  33,  57].  However,  there 
are no reports concerning the direct eﬀect of DCP on 
HCC cell proliferation.  We demonstrated that puri-
ﬁed DCP stimulates DNA synthesis in HCC cell lines 
(Hep3B and SK-Hep-1) in a dose-dependent manner 
[58].  While exploring the signaling pathway for DCP 
stimulation,  we identiﬁed Met,  a hepatocyte growth 
factor receptor,  as a receptor for DCP in HCC cell 
lines [58].  The transductional apparatus of DCP via 
Met was determined to activate the Janus kinase 1 
(JAK1)-signal transducer and activator of transcrip-
tion 3 (STAT3) signaling pathway during cell prolif-
eration (Fig.  3),  indicating that a novel autocrine/
paracrine growth stimulatory mechanism is associated 
with the development of HCC.
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Fig. 2　 A splicing variant of vitamin K-dependent γ-glutamyl carboxy-
lase was identiﬁed in hepatocellular carcinoma cell lines.  Top panel,  
structure of the vitamin K-dependent γ-glutamyl carboxylase (GGCX) 
transmembrane protein.  Exon 2 is located in the ﬁrst GGCX transmem-
brane domain.  Bottom panel,  the gene structure of GGCX derived from 
hepatocellular carcinoma (HCC) cell lines.  The GGCX variant was 
expressed in des-γ-carboxy prothrombin-positive HCC and has an exon 2 
deletion.
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DCP Promotes Vascular Endothelial Cell 
Proliferation and Migration
　 Because HCC tumor arterial vascularity strongly 
correlates with the expression of serum and tissue 
DCP [59],  DCP secreted from HCC cells may act as 
a paracrine interaction factor between HCC cells and 
vascular endothelial cells.
　 Hence,  we assessed the eﬀect of DCP on human 
umbilical vein endothelial cell (HUVEC) proliferation 
and migration as a representative part of angiogenesis 
and found that DCP stimulates HUVEC proliferative 
activity [60].
　 Unlike in HCC cells,  DCP stimulates cell migra-
tory activity in HUVEC; however,  there was no Met 
protein expression or JAK1-STAT3 signaling activa-
tion in DCP-treated HUVEC.  An antibody array 
analysis revealed that the kinase insert domain recep-
tor (KDR),  also known as vascular endothelial growth 
factor receptor 2,  acts as a DCP receptor in HUVEC.
　 The DCP transductional apparatus was shown to 
activate the phospholipase C-γ (PLC-γ)-mitogen-
activated protein kinase (MAPK) signaling pathway via 
activation of KDR (Fig.  3).  Together,  these ﬁndings 
demonstrate a novel paracrine mechanism that is 
involved in the development of HCC-associated angio-
genesis.
Conclusions
　 DCP is a useful prognostic tumor marker for HCC,  
because DCP-positive HCC demonstrates more 
aggressive clinicopathological features than DCP-
negative HCC.  The dominant-negative eﬀect of 
Δ2GGCX may be the molecular mechanism for DCP 
production.  DCP secretion both acts as an autocrine 
driver of HCC cells and exerts a paracrine inﬂuence 
on vascular endothelial cell proliferation and migration 
with respect to angiogenesis.
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